Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
150.46(c) 151.08(c) 157.41(c) 163.26(c) 165.02(c) Last
847 124 470 538 653 503 655 329 709 347 Volume
+3.34% +0.41% +4.19% +3.72% +1.08% Change
More quotes
Financials (USD)
Sales 2021 833 M - -
Net income 2021 -750 M - -
Net cash position 2021 1 382 M - -
P/E ratio 2021 -25,9x
Yield 2021 -
Sales 2022 1 287 M - -
Net income 2022 -433 M - -
Net cash position 2022 1 170 M - -
P/E ratio 2022 -46,6x
Yield 2022 -
Capitalization 19 397 M 19 397 M -
EV / Sales 2021 21,6x
EV / Sales 2022 14,2x
Nbr of Employees 1 453
Free-Float 99,4%
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic... 
Sector
Biotechnology & Medical Research
Calendar
06/15 | 10:00amPresentation
More about the company
Ratings of Alnylam Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ALNYLAM PHARMACEUTICALS, INC.
06/11INSIDER TRENDS : Insider Disposition Eases Back 90-Day Buy Trend at Alnylam Phar..
MT
06/11Vertex Won't Move VX-864 into Late-Stage Testing After Disappointing Study Re..
MT
06/08ALNYLAM PHARMACEUTICALS  : Announces New Data from ATTR Amyloidosis Programs at ..
AQ
06/07ALNYLAM PHARMACEUTICALS  : Announces New Data from ATTR Amyloidosis Programs at ..
BU
06/01ALNYLAM PHARMACEUTICALS  : Completes Enrollment in Phase 3 Study of Patisiran
MT
06/01ALNYLAM PHARMACEUTICALS  : Completes Enrollment in APOLLO-B Phase 3 Study of Pat..
BU
05/26ALNYLAM PHARMACEUTICALS  : to Webcast Presentations at Upcoming June Investor Co..
BU
05/21ALNYLAM PHARMACEUTICALS, INC.  : Submission of Matters to a Vote of Security Hol..
AQ
05/13HEMOPHILIA A PIPELINE : Emerging Therapies and Key pharma players involved by De..
AQ
05/11ALNYLAM PHARMACEUTICALS  : Announces New Advances in ATTR Amyloidosis Program
BU
05/04ALNYLAM PHARMACEUTICALS  : Announces Positive Early Results on Clinical Outcome ..
AQ
05/04ALNYLAM PHARMACEUTICALS  : to Webcast Presentations at Upcoming May Investor Con..
BU
05/03ALNYLAM PHARMACEUTICALS  : Reports Positive Early Results in Phase 3 Study of Ox..
MT
05/03ALNYLAM PHARMACEUTICALS  : Announces Positive Early Results on Clinical Outcome ..
BU
04/29ALNYLAM PHARMACEUTICALS  : Q1 Adjusted Loss Grows
MT
More news
News in other languages on ALNYLAM PHARMACEUTICALS, INC.
04/23DGAP-NEWS : BB BIOTECH AG: Erfolgreiche -2-
2020NOVARTIS : feu vert européen à l'anticholestérol Leqvio
2020ALNYLAM PHARMACEUTICALS  : erhält EU-Zulassung für OXLUMO™ (Lumasiran) zur..
2020ALNYLAM PHARMACEUTICALS  : reçoit l'approbation de l'Union européenne pour OXLUM..
2020ALNYLAM PHARMACEUTICALS  : reçoit un avis positif du CHMP pour OXLUMO™ (lu..
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 172,60 $
Last Close Price 165,02 $
Spread / Highest target 42,4%
Spread / Average Target 4,59%
Spread / Lowest Target -44,9%
EPS Revisions
Managers and Directors
NameTitle
John M. Maraganore Chief Executive Officer & Director
Yvonne L. Greenstreet President & Chief Operating Officer
Jeffrey V. Poulton Chief Financial & Accounting Officer
Michael W. Bonney Chairman
Akshay K. Vaishnaw President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.26.97%19 397
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416